Innoviva (INVA) Stock Forecast, Price Target & Predictions
INVA Stock Forecast
Innoviva stock forecast is as follows: an average price target of $13.00 (represents a -31.83% downside from INVA’s last price of $19.07) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INVA Price Target
The average price target for Innoviva (INVA) is $13.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential -31.83% downside from INVA's last price of $19.07.
INVA Analyst Ratings
According to 2 Wall Street analysts, Innoviva's rating consensus is 'Buy'. The analyst rating breakdown for INVA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Innoviva Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2022 | - | Morgan Stanley | $13.00 | $14.72 | -11.68% | -31.83% |
| Jul 15, 2022 | - | Morgan Stanley | $12.00 | $14.37 | -16.49% | -37.07% |
The latest Innoviva stock forecast, released on Aug 08, 2022 by Morgan Stanley company, set a price target of $13.00, which represents a -11.68% decrease from the stock price at the time of the forecast ($14.72), and a -31.83% decrease from INVA last price ($19.07).
Innoviva Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $19.07 | $19.07 | $19.07 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Innoviva stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Innoviva's last price of $19.07. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 18, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Aug 08, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 15, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Feb 23, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
Innoviva's last stock rating was published by Cantor Fitzgerald on Jun 18, 2024. The company Initialise its INVA rating from "null" to "Overweight".
Innoviva Financial Forecast
Innoviva Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $85.84M | $67.26M | $80.99M | $76.37M | $65.80M | $67.26M | - | $90.06M | $107.68M | $97.86M | $100.81M | $90.48M | $88.69M | $78.95M | $78.68M | $75.97M | $65.75M | $64.11M | $55.18M | $79.86M | $61.68M | $67.09M | $52.38M | $69.52M | $48.64M | $58.56M |
| Avg Forecast | $84.30M | $76.91M | $74.69M | $68.00M | $75.52M | $75.66M | $67.92M | $62.01M | $58.85M | $62.60M | $214.78M | $86.40M | $106.37M | $76.04M | $111.23M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $86.51M | $70.31M | $75.32M | $102.86M | $58.38M | $68.48M | $52.74M |
| High Forecast | $87.50M | $79.83M | $77.52M | $70.58M | $78.38M | $78.53M | $70.50M | $64.36M | $61.09M | $64.98M | $214.78M | $86.40M | $127.64M | $91.25M | $133.48M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $103.82M | $84.37M | $90.38M | $123.43M | $70.06M | $82.18M | $63.29M |
| Low Forecast | $81.11M | $74.00M | $71.86M | $65.43M | $72.66M | $72.79M | $65.35M | $59.66M | $56.62M | $60.23M | $214.78M | $86.40M | $85.09M | $60.83M | $88.99M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $69.21M | $56.25M | $60.25M | $82.29M | $46.70M | $54.79M | $42.19M |
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | 11 | 18 | 15 | 20 | 10 | 10 | 10 | 10 | 8 | 8 | 11 | 8 | 18 | 11 | 16 | 20 | 7 | 14 | 19 |
| Surprise % | - | - | - | - | 1.14% | 0.89% | 1.19% | 1.23% | 1.12% | 1.07% | - | 1.04% | 1.01% | 1.29% | 0.91% | 1.20% | 1.25% | 1.16% | 1.29% | 1.06% | 1.07% | 0.93% | 1.01% | 0.92% | 0.88% | 0.89% | 0.51% | 1.19% | 0.71% | 1.11% |
Innoviva's average Quarter revenue forecast for Mar 24 based on 0 analysts is $68.00M, with a low forecast of $65.43M, and a high forecast of $70.58M. INVA's average Quarter revenue forecast represents a -20.78% decrease compared to the company's last Quarter revenue of $85.84M (Dec 23).
Innoviva EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | 11 | 18 | 15 | 20 | 10 | 10 | 10 | 10 | 8 | 8 | 11 | 8 | 18 | 11 | 16 | 20 | 7 | 14 | 19 |
| EBITDA | - | - | - | - | $44.03M | $100.53M | $19.17M | $51.54M | $28.82M | $30.11M | - | $77.80M | $26.02M | $101.22M | $122.48M | $77.75M | $45.15M | $104.75M | $89.35M | $66.52M | $58.38M | $56.38M | $50.45M | $75.74M | $55.80M | $64.57M | $40.71M | $70.23M | $37.52M | $50.84M |
| Avg Forecast | $67.19M | $61.31M | $59.53M | $42.48M | $60.19M | $60.30M | $54.13M | $38.62M | $46.91M | $49.90M | $171.19M | $35.11M | $17.14M | $72.17M | $88.66M | $62.20M | $62.35M | $54.44M | $48.46M | $57.23M | $59.96M | $68.17M | $43.44M | $81.56M | $62.63M | $71.62M | $54.61M | $56.86M | $48.42M | $45.20M |
| High Forecast | $69.74M | $63.63M | $61.79M | $50.97M | $62.48M | $62.59M | $56.19M | $46.34M | $48.69M | $51.79M | $171.19M | $42.13M | $20.57M | $86.61M | $106.39M | $74.64M | $74.82M | $54.44M | $48.46M | $57.23M | $71.95M | $81.81M | $43.44M | $97.87M | $75.15M | $85.94M | $65.53M | $68.23M | $58.10M | $54.23M |
| Low Forecast | $64.65M | $58.99M | $57.28M | $33.98M | $57.91M | $58.02M | $52.09M | $30.89M | $45.13M | $48.01M | $171.19M | $28.08M | $13.71M | $57.74M | $70.93M | $49.76M | $49.88M | $54.44M | $48.46M | $57.23M | $47.97M | $54.54M | $43.44M | $65.25M | $50.10M | $57.29M | $43.69M | $45.48M | $38.74M | $36.16M |
| Surprise % | - | - | - | - | 0.73% | 1.67% | 0.35% | 1.33% | 0.61% | 0.60% | - | 2.22% | 1.52% | 1.40% | 1.38% | 1.25% | 0.72% | 1.92% | 1.84% | 1.16% | 0.97% | 0.83% | 1.16% | 0.93% | 0.89% | 0.90% | 0.75% | 1.24% | 0.78% | 1.13% |
0 analysts predict INVA's average Quarter EBITDA for Mar 24 to be $42.48M, with a high of $50.97M and a low of $33.98M. This is -3.54% lower than Innoviva's previous annual EBITDA (Dec 23) of $44.03M.
Innoviva Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | 11 | 18 | 15 | 20 | 10 | 10 | 10 | 10 | 8 | 8 | 11 | 8 | 18 | 11 | 16 | 20 | 7 | 14 | 19 |
| Net Income | - | - | - | - | $61.53M | $82.05M | $1.28M | $34.87M | $-68.31M | $265.52M | - | $37.86M | $45.65M | $102.65M | $88.95M | $75.02M | $41.62M | $76.84M | $65.44M | $45.95M | $39.81M | $37.74M | $33.79M | $263.76M | $47.09M | $54.63M | $19.22M | $58.38M | $7.51M | $22.46M |
| Avg Forecast | $20.01M | $16.57M | $14.69M | $22.99M | $14.38M | $16.88M | $16.26M | $20.90M | $14.07M | $65.34M | $123.98M | $19.00M | $6.81M | $51.65M | $98.15M | $43.12M | $38.97M | $65.37M | $57.66M | $53.30M | $40.88M | $45.64M | $38.48M | $284.05M | $52.85M | $60.59M | $39.68M | $47.26M | $30.67M | $31.24M |
| High Forecast | $21.00M | $19.76M | $15.42M | $27.59M | $15.09M | $17.72M | $17.06M | $25.08M | $14.76M | $78.41M | $123.98M | $22.80M | $8.18M | $61.98M | $117.78M | $51.75M | $46.76M | $78.45M | $69.19M | $63.96M | $49.06M | $54.77M | $46.18M | $340.86M | $63.43M | $72.70M | $47.62M | $56.72M | $36.80M | $37.49M |
| Low Forecast | $19.02M | $14.02M | $13.97M | $18.39M | $13.67M | $16.05M | $15.46M | $16.72M | $13.38M | $52.27M | $123.98M | $15.20M | $5.45M | $41.32M | $78.52M | $34.50M | $31.17M | $52.30M | $46.13M | $42.64M | $32.71M | $36.51M | $30.79M | $227.24M | $42.28M | $48.47M | $31.75M | $37.81M | $24.53M | $24.99M |
| Surprise % | - | - | - | - | 4.28% | 4.86% | 0.08% | 1.67% | -4.86% | 4.06% | - | 1.99% | 6.70% | 1.99% | 0.91% | 1.74% | 1.07% | 1.18% | 1.13% | 0.86% | 0.97% | 0.83% | 0.88% | 0.93% | 0.89% | 0.90% | 0.48% | 1.24% | 0.24% | 0.72% |
Innoviva's average Quarter net income forecast for Mar 24 is $22.99M, with a range of $18.39M to $27.59M. INVA's average Quarter net income forecast represents a -62.64% decrease compared to the company's last Quarter net income of $61.53M (Dec 23).
Innoviva SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | 11 | 18 | 15 | 20 | 10 | 10 | 10 | 10 | 8 | 8 | 11 | 8 | 18 | 11 | 16 | 20 | 7 | 14 | 19 |
| SG&A | - | - | - | - | $26.32M | $28.64M | $23.54M | $19.73M | $17.39M | $27.81M | - | $6.49M | $3.11M | $2.86M | $4.23M | $5.47M | $3.25M | $2.60M | $2.56M | $2.33M | $4.96M | $4.35M | $3.02M | $2.64M | $4.02M | $4.41M | $11.69M | $2.77M | $8.31M | $10.38M |
| Avg Forecast | $10.67M | $9.74M | $9.46M | $9.46M | $9.56M | $9.58M | $8.60M | $8.60M | $7.45M | $2.58M | $27.19M | $7.82M | $2.05M | $2.04M | $4.67M | $4.38M | $4.49M | $2.21M | $2.26M | $2.71M | $5.10M | $5.26M | $3.43M | $2.84M | $4.51M | $4.89M | $15.68M | $2.24M | $10.72M | $9.23M |
| High Forecast | $11.08M | $10.11M | $9.81M | $11.35M | $9.92M | $9.94M | $8.92M | $10.32M | $7.73M | $3.10M | $27.19M | $9.38M | $2.46M | $2.45M | $5.60M | $5.25M | $5.39M | $2.65M | $2.71M | $3.25M | $6.12M | $6.31M | $4.12M | $3.41M | $5.41M | $5.87M | $18.81M | $2.69M | $12.87M | $11.08M |
| Low Forecast | $10.27M | $9.37M | $9.10M | $7.57M | $9.20M | $9.22M | $8.27M | $6.88M | $7.17M | $2.06M | $27.19M | $6.26M | $1.64M | $1.63M | $3.73M | $3.50M | $3.59M | $1.77M | $1.81M | $2.16M | $4.08M | $4.21M | $2.75M | $2.27M | $3.61M | $3.91M | $12.54M | $1.79M | $8.58M | $7.38M |
| Surprise % | - | - | - | - | 2.75% | 2.99% | 2.74% | 2.29% | 2.33% | 10.78% | - | 0.83% | 1.52% | 1.40% | 0.91% | 1.25% | 0.72% | 1.18% | 1.13% | 0.86% | 0.97% | 0.83% | 0.88% | 0.93% | 0.89% | 0.90% | 0.75% | 1.24% | 0.78% | 1.13% |
Innoviva's average Quarter SG&A projection for Mar 24 is $9.46M, based on 0 Wall Street analysts, with a range of $7.57M to $11.35M. The forecast indicates a -64.05% fall compared to INVA last annual SG&A of $26.32M (Dec 23).
Innoviva EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | 11 | 18 | 15 | 20 | 10 | 10 | 10 | 10 | 8 | 8 | 11 | 8 | 18 | 11 | 16 | 20 | 7 | 14 | 19 |
| EPS | - | - | - | - | $0.72 | $1.26 | $0.02 | $0.51 | $-0.98 | $3.81 | - | $0.54 | $0.66 | $1.48 | $1.01 | $0.74 | $0.41 | $0.76 | $0.65 | $0.45 | $0.39 | $0.37 | $0.33 | $2.61 | $0.47 | $0.54 | $0.19 | $0.55 | $0.07 | $0.21 |
| Avg Forecast | $0.32 | $0.27 | $0.23 | $0.17 | $0.23 | $0.27 | $0.26 | $0.23 | $0.23 | $1.53 | $1.47 | $0.44 | $0.41 | $0.43 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.70 | $0.55 | $0.61 | $0.71 | $0.34 | $0.40 | $0.24 |
| High Forecast | $0.34 | $0.32 | $0.25 | $0.18 | $0.24 | $0.28 | $0.27 | $0.24 | $0.24 | $1.61 | $1.47 | $0.44 | $0.41 | $0.43 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.84 | $0.66 | $0.73 | $0.85 | $0.41 | $0.48 | $0.29 |
| Low Forecast | $0.30 | $0.22 | $0.22 | $0.16 | $0.22 | $0.26 | $0.25 | $0.22 | $0.21 | $1.45 | $1.47 | $0.44 | $0.41 | $0.43 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.56 | $0.44 | $0.49 | $0.57 | $0.27 | $0.32 | $0.19 |
| Surprise % | - | - | - | - | 3.13% | 4.67% | 0.08% | 2.22% | -4.36% | 2.49% | - | 1.23% | 1.61% | 3.44% | 3.48% | 1.85% | 0.98% | 2.38% | 1.81% | 0.91% | 1.07% | 0.87% | 0.92% | 3.73% | 0.85% | 0.89% | 0.27% | 1.62% | 0.18% | 0.88% |
According to 0 Wall Street analysts, Innoviva's projected average Quarter EPS for Mar 24 is $0.17, with a low estimate of $0.16 and a high estimate of $0.18. This represents a -76.39% decrease compared to INVA previous annual EPS of $0.72 (Dec 23).
Innoviva Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| ELEV | Elevation Oncology | $0.63 | $9.00 | 1328.57% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| PDSB | PDS Bio | $2.93 | $9.00 | 207.17% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| DNLI | Denali Therapeutics | $25.25 | $40.00 | 58.42% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| HRMY | Harmony Biosciences | $35.59 | $49.60 | 39.36% | Buy |
| INCY | Incyte | $61.26 | $81.00 | 32.22% | Buy |
| FOLD | Amicus Therapeutics | $11.65 | $15.33 | 31.59% | Buy |
| ARGX | argenx SE | $542.00 | $446.55 | -17.61% | Buy |
| INVA | Innoviva | $19.07 | $13.00 | -31.83% | Buy |
| HOOK | HOOKIPA Pharma | $4.74 | $3.00 | -36.71% | Buy |
INVA Forecast FAQ
Is Innoviva a good buy?
Yes, according to 2 Wall Street analysts, Innoviva (INVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of INVA's total ratings.
What is INVA's price target?
Innoviva (INVA) average price target is $13 with a range of $13 to $13, implying a -31.83% from its last price of $19.07. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Innoviva stock go up soon?
According to Wall Street analysts' prediction for INVA stock, the company can go down by -31.83% (from the last price of $19.07 to the average price target of $13), down by -31.83% based on the highest stock price target, and down by -31.83% based on the lowest stock price target.
Can Innoviva stock reach $30?
INVA's average twelve months analyst stock price target of $13 does not support the claim that Innoviva can reach $30 in the near future.
What are Innoviva's analysts' financial forecasts?
INVA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $303.9M (high $315.44M, low $292.4M), average EBITDA is $230.5M (high $246.14M, low $214.89M), average net income is $74.26M (high $83.76M, low $65.41M), average SG&A $39.33M (high $42.35M, low $36.3M), and average EPS is $0.99 (high $1.08, low $0.914).
Did the INVA's actual financial results beat the analysts' financial forecasts?
Based on Innoviva's last annual report (Dec 2023), the company's revenue was $310.46M, beating the average analysts forecast of $281.1M by 10.45%. Apple's EBITDA was $176.71M, missing the average prediction of $213.24M by -17.13%. The company's net income was $179.72M, beating the average estimation of $68.42M by 162.68%. Apple's SG&A was $98.23M, beating the average forecast of $36.34M by 170.32%. Lastly, the company's EPS was $2.07, beating the average prediction of $0.99 by 109.09%. In terms of the last quarterly report (Dec 2023), Innoviva's revenue was $85.84M, beating the average analysts' forecast of $75.52M by 13.67%. The company's EBITDA was $44.04M, missing the average prediction of $60.19M by -26.84%. Innoviva's net income was $61.53M, beating the average estimation of $14.38M by 327.86%. The company's SG&A was $26.32M, beating the average forecast of $9.56M by 175.30%. Lastly, the company's EPS was $0.72, beating the average prediction of $0.23 by 213.04%